Abstract
Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Current Drug Targets
Title: Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Volume: 2 Issue: 3
Author(s): Gene C. Palmer
Affiliation:
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Abstract: Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Export Options
About this article
Cite this article as:
Palmer C. Gene, Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348335
DOI https://dx.doi.org/10.2174/1389450013348335 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines
CNS & Neurological Disorders - Drug Targets Cerebral Hypoperfusion in Hereditary Coproporphyria (HCP): A Single Photon Emission Computed Tomography (SPECT) Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets AED Strategy after Refractory Epilepsy Surgery
Current Pharmaceutical Design The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Nanomaterials for Neurology: State-of-the-Art
CNS & Neurological Disorders - Drug Targets The Effect of Lamotrigine on Valproic Acid Concentrations
Current Drug Safety The Effect of Mianserin on Lifespan of <i>Caenorhabditis elegan</i> is Abolished by Glucose
Current Aging Science TrkB Receptor Agonist 7, 8 Dihydroxyflavone Triggers Profound Gender- Dependent Neuroprotection in Mice After Perinatal Hypoxia and Ischemia
CNS & Neurological Disorders - Drug Targets Therapeutic Potential and Prospects of L-arginine in Various Diseases and its Clinical Intervention
Current Drug Therapy Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Biological Evaluation of Imidazobenzoxazines, Imidazobenzoxazin-5-ones and Imidazobenzoxazin-5-thiones as Sodium Channel Blockers
Letters in Drug Design & Discovery Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Current Pharmaceutical Design Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System
Current Neuropharmacology The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design